Hemarthroses
Recurrenthemarthroses
The importance of rapid bleeding controlHemophilia patients with inhibitors present a special challenge
“ The time taken to stop a
bleeding episode is very
important to the patient
as it reduces the time
a patient is in pain, the
amount of hemostatic agent
required, the potential
long-term damage to the
joint, and the subsequent
cost of undergoing a joint
arthroplasty.”
The vicious cycle of joint damage8
In the long term, the presence of blood in the joint leads to chronic synovitis, development
of a target joint, and progressive arthropathy8
Difficult to manage4,5,6
Poorer outcome following joint bleeds7
Greater risk of long-term joint damage and disability7
Delaying treatment results in:10
- Longer time to bleeding resolution
- A larger number of doses required to stop the bleeding
- Increased costs
Clinical guidelines for hemophilia emphasise the importance of early intervention
NiaStase RT® acts here
NiaStase RT® (eptacog alfa, activated) is indicated in hemophilia A/B patients with inhibitors to FVIII or FIX, respectively, for the treatment of bleeding episodes (including treatment and prevention of those occurring during and after surgery).3 Long term efficacy has not been established.